AHB-137 is cleared for initiation of a clinical trial in CHB patients in the US AHB-137 is an unconjugated antisense oligonucleotide (ASO) aimed for functional cure of CHB SAN FRANCISCO, Aug. 25, 2023 /PRNewswire/ — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (Together…
AusperBio Announces FDA Clearance of IND Application of AHB-137 in Chronic Hepatitis B Treatment
This post was originally published on this site